New Japanese patent approval for Episurf Medical
The Japanese patent office JPO has announced its intention to grant another Japanese patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Method and node for manufacturing a surgical kit for cartilage repair”, covers the medical image segmentation process used for joint damage visualisation as well as for manufacturing of Episurf Medical’s individualised joint implants and surgical instruments.
"This patent family gives important protection for Episurf’s technology, and we are happy to see how it gets more and more approvals globally”, comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CEDT on 6 July 2018.
Tags: